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SUMMARY – Chronic heart failure places heavy burden on patients, their families and on health 
care resources, accounting for high numbers of hospital admissions. Despite huge improvements in 
the treatment of many heart disorders, the clinical syndrome of chronic heart failure as a fi nal pathway 
of heart pathology is an exception, in that its prevalence is rising, and only small prolongations in 
survival are occurring. It is associated with high morbidity and poor prognosis, and a survival rate 
worse than that for some malignant tumors. Th e reasons for the increasing overall prevalence of 
chronic heart failure in developed countries lie in prolonged survival owing to modern pharmacologi-
cal or invasive treatment, better secondary prevention, and aging of the population. Chronic pulmo-
nary disease is common in patients with chronic heart failure. Th rough sharing some risk factors and 
overlapping pathophysiological processes, they present diagnostic and therapeutic challenge. Th e aim 
of this article is to review various mechanisms responsible for the symptoms of chronic heart failure 
with consecutive pulmonary interaction and abnormalities in lung function.
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Introduction
Chronic heart failure (CHF) is a clinical syndrome 
defi ned by the presence of symptoms, most often as 
breathlessness and fatigue, and objective clinical signs 
such as evidence of fl uid retention, tachypnea, tachy-
cardia, pleural eff usion, pulmonary rales, or ankle 
swelling. Of course, to establish the diagnosis, these 
clinical data have to be combined with objective evi-
dence for structural or functional abnormality of the 
heart. CHF is always a result of the underlying cardiac 
disease irrespective of whether it involves the myocar-
dium, endocardium with valvar apparatus, or pericar-
dium. Th e incidence of CHF is reported to be between 
2.0% and 5.0 cases per 1000 people per year in western 
countries, with the increase in the incidence to up to 
40 cases per 1000 people per year in the population 
older than 75 years. Th e prevalence of this condition is 
estimated to be around 3% with a rise in the preva-
lence to between 3.0% and 13.0% in the population 
older than 651. Th e reasons for the increasing overall 
prevalence of CHF in developed countries lie in pro-
longed survival owing to modern pharmacological or 
invasive treatment, better secondary prevention, and 
aging of the population. Th us, overall expenditures are 
rising with approximately 2% of national health bud-
gets being spent on the treatment of these patients2. 
Th e prognosis in CHF is generally poor. A population 
based study, Framingham Heart Study, showed the 
median survival of 3.2 years in men and 5.4 years in 
women after establishing the diagnosis3. Also, mortal-
ity as a consequence of CHF increases with age, show-
ing a 27% increase in mortality in men with every de-
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cade of life and 61% increase in women of older age 
groups4. Th e aim of this article is to review the cardio-
pulmonary interaction of CHF with consecutive pul-
monary abnormalities. Th e pathophysiology and treat-
ment of acute heart failure was not considered.
Mechanism and Clinical Impact of Dyspnea 
in Chronic Heart Failure
Dyspnea or breathlessness is the most common 
symptom of CHF, largely due to the lower quality of 
life in these patients. Clinical follow-up, treatment and 
prognostication in CHF have been traditionally based 
on the New York Heart Association Functional Clas-
sifi cation (NYHA), which is based on clinical criteria, 
primarily dyspnea and exercise intolerance. Shortness 
of breath or dyspnea is a product of a well-defi ned, 
complicated interaction between periphery and cortex 
of the brain. Namely, various receptors contribute to 
the process. Hypoxia stimulates peripheral and central 
chemoreceptors: mechanical stimuli activate mecha-
noreceptors in upper airways of the chest wall, whereas 
lung comprises pulmonary stretch receptors, which are 
activated by lung infl ation; irritant receptors are acti-
vated with chemical stimuli, which promote broncho-
constriction and C-fi bers that are placed in the inter-
stitium and react to pulmonary congestion5. Breath-
lessness in CHF is mainly based on the increased 
breathing eff ort secondary to changes of lung or chest 
wall mechanics and respiratory musculature weakness, 
although a signifi cant role is played by pulmonary con-
gestion and changes in lung function. Many patients 
in stable condition with no volume overload, unlike 
subjects with chronic pulmonary diseases, are not hy-
poxemic. Changes in lung and chest wall mechanics 
take place due to fl uid retention. Left ventricular fail-
ure leads to higher end-diastolic ventricular pressure 
and pulmonary venous hypertension. Th ere is a gradu-
al increase in pulmonary blood fl ow from the apex to 
the base of the lung, which can be expected. Elevated 
pressure makes blood fl ow uniformly spread and redis-
tributed across the lung. Th is pulmonary blood fl ow 
redistribution is accomplished through capillary re-
cruitment. If the rise of the pulmonary venous pres-
sures continues, fl uid would cross the alveolocapillary 
barrier. Th is process has been traditionally defi ned 
since Starling fi rst described the basic forces regulating 
fl uid migration, with hydrostatic forces favoring the 
crossing of the fl uid to alveolar spaces and interstitial 
oncotic pressures supporting retention of the fl uid in 
the interstitial spaces. Over time, the fl uid is being re-
tained in interlobular septa, peribronchovascular inter-
stitium and pleural space with lymphatic system clear-
ing the water overload. Alveolocapillary membrane 
changes with thickening and fi brosis taking place, 
which reduces the permeability for fl uid. Also, pulmo-
nary veins become thicker and pulmonary arterioles 
show intimal fi brosis and media thickening. Th ese 
changes are responsible for relative resistance of the 
interstitium to high capillary pressures and have been 
designated as an explanation of how patients with 
CHF tolerate high pulmonary capillary wedge pres-
sures without experiencing pulmonary edema. Fluid 
overload in the interstitium, peribronchovascular, hilar 
and pleural spaces is responsible for lower pulmonary 
compliance and higher chest stiff ness. Because of the 
long-lasting process of pulmonary venous hyperten-
sion in CHF, sometimes damage to alveolocapillary 
area occurs6. Namely, tearing of alveolar epithelium, 
capillary endothelium and collagen structures of basal 
membranes takes place and is responsible for extrava-
sation of red blood cells into the alveolar spaces (Fig. 
1). Th is process has been termed pulmonary capillary 
stress failure. Also, this explains the higher content of 
hemosiderin in alveolar spaces in patients with long-
Fig. 1. Histopathologic evaluation of lung edema.
Hematoxylin and eosin histologic analysis shows alveolar 
walls that are thickened due to distention of capillaries 
and interstitial edema. Alveolar lumen is fi lled with 
transudate and blood (a homogeneous red-pink material) 
consistent with the diagnosis of lung edema (low-power 
photomicrograph, original magnifi cation, x100).
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standing chronic heart failure, sometimes leading even 
to pulmonary ossifi cation. Such changes have been es-
pecially well described in patients with long-standing 
mitral stenosis7.
Th e Role of Respiratory Musculature 
in Dyspnea and Exercise Intolerance 
in Patients with Chronic Heart Failure
Respiratory eff ort can be simply defi ned by the 
sense of ‘breathing work’ needed to fulfi ll ventilatory 
demand in a hypothetical situation. Th is awareness of 
eff ort is a function of the ratio between generated work 
achieved by respiratory muscles in that hypothetical 
situation and their maximum capability. Th us, the 
sense of eff ort is increased whenever muscles have to 
generate greater pressure in order to compensate for 
extra load (such as higher elastic or resistive forces of 
the lung or chest), or when there is lower pressure gen-
erating the capacity of muscles (intrinsic weakness of 
the respiratory musculature, increase in the chest vol-
ume, fatigue of the musculature). A large number of 
experimental and clinical works have been dedicated 
to enlighten the role of respiratory musculature in 
CHF. Most of the work of breathing is done by the 
diaphragm consisting of ‘slow oxidative-fatigue resis-
tant’ fi bers, which are, on the other hand, very perfu-
sion sensitive. It has been shown that patients with 
CHF have a signifi cantly reduced strength of respira-
tory musculature as compared with healthy individuals 
of the same age8. Moreover, in these patients, muscle 
strength of other regions in the body has not been re-
duced in that scale, leading to a conclusion that respi-
ratory muscles depend more on the cardiac output but 
there are reports suggesting that this disorder is a gen-
eral one, with respiratory muscles to be aff ected earli-
er9. McParland et al. proved that respiratory muscle 
strength was reduced in patients with CHF, and what 
is more, that this reduction of respiratory muscle 
strength correlated with dyspnea on performing every-
day activities10.
In another study, McParland et al. confi rmed these 
fi ndings and found no connection of muscle weak-
ness with nutritional or electrolyte status in patients 
with CHF11. Mancini et al. demonstrated hypoxia 
to take place in respiratory muscles during exercise in 
patients with CHF; in a subsequent study, Mancini 
et al. showed not only linear connection between respi-
ratory muscle strength and dyspnea, but also changes 
of diaphragm workload and lack of muscle fatigue 
during exercise in patients with cardiac failure12,13. 
In another study by Evans et al., weakness of respira-
tory muscles in CHF was found again, but without 
correlation with dyspnea or exercise intolerance14. Re-
spiratory muscle endurance defi ned as the ability of 
the muscle to resist fatigue is a sign of respiratory 
 musculature dysfunction, which is depressed in CHF 
patients and tends to correlate with their exercise in-
tolerance15,16. Relative inconclusiveness of various 
studies regarding the connection between respiratory 
muscle dysfunction and dyspnea or exercise intoler-
ance may be a consequence of diff erent methodology, 
small number of patients, or variability of patient char-
acteristics. Nevertheless, rehabilitation and training of 
inspiratory muscles in patients with CHF showed 
clear benefi t17-19.
Lung Function in Chronic Heart Failure
Changes in lung functions in patients with CHF 
have been well studied. As regards the fact that dys-
pnea is the most frequent of all symptoms in these pa-
tients, great interest was directed towards understand-
ing of the underlying process. Respective studies used 
pulmonary function testing and showed that patients 
with CHF predominantly had a restrictive pattern of 
breathing. Th ere are several reasons that can explain 
such fi ndings. Firstly, these patients exhibit volume 
overload with liquid retention in pulmonary intersti-
tial, alveolar and pleural spaces. Secondly, the size of 
the heart is enlarged. Agostoni et al. conducted a study 
in which cardiothoracic index on conventional chest 
x-ray correlated inversely with the parameters of lung 
function20. Th irdly, stiff ness of the lung due to water 
retention contributes as well. Bearing the fact of 
unique thoracic space in mind, which comprises heart, 
lungs and other structures in a given volume, these 
changes are directly reducing the useful lung volume. 
Indeed, the relation between cardiomegaly and dete-
rioration of lung function was directly studied show-
ing positive correlation20. Lung function testing in 
CHF predominantly shows reduced total lung capac-
ity (TLC) and forced vital capacity (FVC)21-23. Conse-
quently, the ratio between forced expiratory volume in 
fi rst second (FEV1) and FVC is increased. Also, re-
sidual volume tends to be increased with reduction of 
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vital capacity. Namely, accumulation of retained liquid 
in peribronchovascular spaces leads to erection of dis-
tended vessels and compression of bronchioles with air 
trapping24. After intensive diuretic treatment or heart 
transplantation, all of these changes tend to be cor-
rected25-27. Acute heart failure shows completely diff er-
ent lung function disturbance patterns with predomi-
nantly obstructive changes in lung function testing28,29. 
Th is explains wheezing in clinical presentation of such 
patients. Th e reason for this lies in airway obstruction 
due to wall congestion of smaller airways. All of these 
changes have also been shown to improve following 
diuretic therapy, although it is interesting that bron-
chodilator therapy did not improve airway obstruc-
tion28. Finally, bronchial hyperreactivity in CHF may 
play a signifi cant role. Th is can be explained by conges-
tion and thickening of the bronchial mucosa layer with 
activation of irritant receptors and C-fi bers. Vagotomy 
in experimental animals put in the setting of cardiac 
failure has shown betterment of lung function30. In-
deed, patients with CHF were shown to have signifi -
cantly higher bronchial hyperreactivity with acetyl-
choline inhalation testing31. Lung function during 
physical activity in patients with CHF shows striking 
change with regard to the pathologic pattern of venti-
lation in which patients produce higher respiratory 
rate with low tidal volume, in contrast to healthy sub-
jects where physical demand is met with the increase 
in both tidal volume and respiratory frequency, yield-
ing a higher ventilation rate in patients with conges-
tive CHF for a given workload. Th ere are several ex-
planations, most important being changes in lung me-
chanics with the increase in the overall chest volume 
and stiff ness, lower lung compliance, all of which make 
respiratory muscles ineff ective, weak and prone to fa-
tigue. Moreover, lung diff usion is reduced and dead 
space ventilation is increased23. Th is hyperventilating 
pattern correlates with the rate of dyspnea and physi-
cal exercise intolerance32,33. Also, the severity and prog-
nosis of CHF can be estimated with low ventilatory 
effi  ciency defi ned as high ventilation drive relative to 
the given carbondioxide production34-36.
Lung Diff usion in Chronic Heart Failure
Gas diff usion takes place at the alveolocapillary 
membrane which, in a simplifi ed model, consists of al-
veolar epithelium, capillary endothelium, and their 
basal membranes. Electron microscopy has shown that 
this membrane is not uniformly structured but is com-
posed of a thinner and thicker part with regard to the 
interstitial matrix content. On the thinner side, capil-
lary endothelium and alveolar epithelium are closely 
positioned with tight junctions and basal membranes 
fused, whereas on the thicker side these structures are 
mediated by the protein-rich interstitium37. Th in part 
of the membrane is designed to optimally fulfi ll the 
task of gas diff usion, and the thick part, in the setting 
of higher hydrostatic pressures (as in CHF), takes over 
the fl uid and removes it from the critical area where 
gas diff usion takes place. Generally, diff using capacity 
of the lung for carbon monoxide (DLCO) is a func-
tion of membrane conductance on the one hand, and 
of the blood volume in the capillaries with the rate of 
hemoglobin on the other hand. Patients with CHF 
were shown to have reduced DLCO with linear dete-
rioration of lung diff usion in patients with more severe 
CHF38-40. Th e reason for reduced DLCO presumably 
lies in chronic changes of the alveolocapillary mem-
brane with fl uid accumulation, fi brosis, and subsequent 
reduction of membrane conductance. Also, this reduc-
tion is obviously not compensated enough with larger 
volume of capillary blood fl ow as would be expected 
giving the fact of pulmonary venous hypertension in 
these patients. Also, these changes are not completely 
reversible because patients after heart transplantation 
keep approximately the same DLCO as before the op-
eration41,42. After heart transplantation, DLCO tends 
to decline at fi rst, which probably resembles the de-
cline in capillary blood fl ow due to reduction in pul-
monary venous pressure43-45. All these changes show 
that DLCO reduction in patients with CHF does not 
depend solely on fl uid retention but rather is a long-
lasting process with formation of chronic changes to 
alveolocapillary membrane, or may be a consequence 
of accompanying pulmonary disease. Th is conclusion 
is supported by the fact that ultrafi ltration in patients 
with CHF improves lung volumes and mechanical 
properties of the lung but is unable to improve DLCO, 
which means that this parameter is not completely 
fl uid-dependent46. Impaired lung diff usion was shown 
to be related to depressed exercise capacity in patients 
with heart failure47-49. Also, membrane conductance, of 
all respiratory function parameters, correlated best 
with exercise ventilation effi  ciency and prognosis in 
patients with heart failure50,51. Exercise training in pa-
I. Alerić et al. Cardiopulmonary interactions
530 Acta Clin Croat, Vol. 56, No. 3, 2017
tients with heart failure can improve DLCO and exer-
cise performance52.
Ventilation-Perfusion Mismatch 
in Chronic Heart Failure
As mentioned above, redistribution of pulmonary 
capillary perfusion takes place in patients with cardiac 
failure due to pulmonary venous hypertension and vol-
ume overload. Changes of lung volumes and mechan-
ics also occur. Th is makes patients with CHF more 
prone to ventilation-perfusion mismatching. In nor-
mal conditions, there is no alveolar dead space but, 
rather, dead space is a consequence of anatomic dead 
space. It has been shown that exercise ventilation pat-
tern in CHF is a pathologic one with hyperventilation 
and low effi  ciency. Th e reason, among others men-
tioned earlier, lies in the inability of the lung to aug-
ment tidal volume during exercise, which makes 
breathing in these conditions shallow and rapid. Also, 
the ratio between the dead space volume and tidal vol-
ume stays constant in exercise, suggesting that there 
are areas of high ventilation-perfusion mismatch with 
under perfused alveolar spaces, probably due to low 
cardiac output53. Th ese facts when summarized bring 
us to a conclusion that there is a connection between 
low effi  cient breathing, exercise intolerance and venti-
lation-perfusion mismatch with high respiratory drive 
to compensate for the under perfused areas of the 
lung54.
Sleep Disordered Breathing 
in Chronic Heart Failure
Chronic heart failure is tightly connected with 
sleep-disordered breathing (SDB). SDB can be divid-
ed into obstructive sleep apnea/hypopnea (OSA), 
which is defi ned as fi ve or more apnea/hypopnea epi-
sodes per hour (apnea/hypopnea index, AHI) that oc-
cur due to obstruction of upper airways, combined 
with extreme respiratory eff ort and central sleep apnea 
(CSA), which is defi ned the same as OSA but without 
traceable respiratory eff ort during apnea/hypopnea 
episodes55-60. Both OSA and CSA can coexist in some 
patients. CSA can be accompanied with Cheyne-
Stokes respiration, periodic breathing where apneas 
alternate with rapidly emerging and waning ventila-
tion. Among patients with CHF, 50% of them suff er 
from SDB, with 80% of them having CSA and the rest 
having OSA61. OSA/CSA result in repetitive oxyhe-
moglobin desaturations with consequential arousals, 
activation of sympathetic system, and increase in arte-
rial blood pressure. OSA is thought to be a major caus-
al factor for cardiovascular diseases and CHF, fi rstly 
through its clear eff ect on the incidence of arterial hy-
pertension as a major cardiovascular risk factor, then 
through mechanical and hemodynamic eff ects of neg-
ative intrathoracic pressures; OSA has also been asso-
ciated with activation of the sympathetic nervous sys-
tem, endothelial dysfunction and systemic infl amma-
tion62-67. CSA with or without Cheyne-Stokes respira-
tion pattern is a consequence of CHF. Th is form of 
SDB occurs due to instability of the respiratory system 
in patients with CHF68-69. Respiration during sleep is 
controlled by the interaction between brainstem cen-
ters, respiratory apparatus (inspiratory musculature, 
pulmonary parenchyma) and chemoreceptors. Tight 
correlation between the ventilatory cycle duration and 
left ventricular ejection fraction has led to a conclusion 
that low cardiac output and timely transport of the 
chemostimuli to the chemoreceptors are responsible 
for the prolonged ventilatory cycle in CHF patients70. 
Th us, chemoreceptors produce an exaggerated answer 
to low partial pressures of carbon dioxide, fi nally lead-
ing to apnea or hypopnea. Low partial pressure of car-
bon dioxide is, on the other hand, a consequence of 
hyperventilation or high respiratory drive in CHF. It is 
believed that partial pressure of carbon dioxide is the 
most important indicator of respiratory drive control, 
as confi rmed by a study with reversal of CSA with car-
bon dioxide inhalation71. CSA can worsen the existing 
CHF through its eff ect on further activation of the 
sympathetic system, hypoxemia, blood pressure varia-
tions, and cardiac arrhythmia, and also worsens the 
prognosis with increase of mortality in patients with 
higher AHI72. Sleep breathing disorders in CHF can 
be improved with treatment. OSA has been success-
fully treated with continuous positive airway pres-
sure68. Studies with optimization of chronic pharma-
cotherapy have shown success in treating CSA in pa-
tients with CHF; supplementing oxygen via nasal 
cannula has also been shown eff ective74,75. Th e admin-
istration of bronchodilation agents showed benefi cial 
eff ect on SDB and acetazolamide-mild diuretic given 
before sleep produces mild metabolic acidosis, there-
fore decreases partial pressure of carbon dioxide and 
resets the apnea/hypopnea threshold resulting in fewer 
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episodes of apnea, better oxyhemoglobin saturation, 
and improving the quality of sleep76,77. Noninvasive 
continuous positive airway pressure treatment reduces 
sympathetic system activation, arrhythmia incidence, 
arterial hypertension, and improves left ventricular 
ejection fraction and volume78,79. Th ere is no clear ef-
fect on mortality reduction80.
Radiographic Manifestation 
of Chronic Heart Failure
Chronic heart failure with pulmonary venous hy-
pertension and volume overload brings along charac-
teristic radio-morphological changes in thoracic imag-
ing. Conventional chest radiogram has been tradition-
ally considered to be the most appropriate tool for di-
agnosis and follow-up of CHF. Normally, pulmonary 
blood fl ow has its characteristic distribution pattern 
with better perfused area of the lung being its basal 
part and less perfused area of the lung being the apex, 
accordingly with gravitational force. Pulmonary blood 
fl ow is a low-pressure and low-resistance system with 
large capacity for accommodation in case of pulmo-
nary venous hypertension and volume overload. Rise 
in left ventricular end-diastolic pressure, which can be 
approximated with the rise in pulmonary capillary 
wedge pressure, in patients with CHF leads to changes 
in pulmonary blood fl ow. Capillaries in the apical parts 
of the lung, previously collapsed, are being recruited 
and those in the base of the lung are being distended. 
Th is change in physiological perfusion of the lung is 
called redistribution of the pulmonary blood fl ow. 
Logically, pulmonary artery-to-bronchus diameter ra-
tio changes as well. Namely, with volume overload ar-
teries gain greater diameter and surpass diameter of 
the accompanying bronchus, especially in lower parts 
of the lung81. Cardiomegaly is another typical radio-
graphic sign of congestive CHF, although not espe-
cially sensitive or specifi c. It has sensitivity of 50% and 
specifi city of around 75%. Cardiomegaly is best appre-
ciated through cardiothoracic ratio. Th is ratio is calcu-
lated by dividing transverse cardiac diameter with 
transverse chest diameter measured on chest x-ray, and 
cardiomegaly is present when the ratio surpasses 50%. 
Another feature of the heart silhouette on chest x-ray, 
vascular pedicle, which comprises great intrathoracic 
vessels, widens on chest x-ray. Th is pedicle is routinely 
measured as a fi eld that is limited on the right with 
superior vena cava and on the left with the point of the 
subclavian artery take-off . Normally, this diameter is 
6.0 centimeters or less and is considered pathological 
when 8.5 centimeters or greater. Th e azygos vein seen 
on the chest x-ray when dilated is a sign of increased 
right atrial pressure. Normal diameter of the vein is 
about 7.0 millimeters and when the diameter is 10.0 or 
more millimeters, it should be considered abnormal 
and suggests volume overload. As pulmonary venous 
pressure keeps rising, interstitial edema is formed82,83. 
It is a consequence of fl uid leakage into the interlobu-
lar and peribronchial interstitium. When the fl uid 
leaks into peripheral interlobular interstitium, it can be 
appreciated as Kerley B lines on chest x-ray. Th ese are 
peripherally mounted small horizontal lines that run 
perpendicularly to the pleura. Edema of the peribron-
chial interstitium presents as bronchial wall thicken-
ing. If pulmonary venous pressure would increase fur-
ther, alveolar edema and fl ooding of alveolar spaces 
would take place. Computerized tomography of the 
chest is not a method of choice for screening or fol-
low-up of patients with CHF for being expensive, 
relatively inaccessible, and associated with high radia-
tion dose, although patients with CHF demonstrate 
typical fi ndings such as interstitial edema with thick-
ened septal lines and ground glass opacities in depen-
dent part of the lung82-84 (Fig. 2).
Fig. 2. Radiological evaluation of chronic heart failure.
Chest radiograph of a 65-year-old man with chronic 
cough and dilatative cardiomyopathy shows interstitial 
abnormalities. Kerley B lines are notably present 
in both lung lobes. Cardiomegaly and distension 
of the right upper lobe and the right lower lobe veins 
suggest the diagnosis of chronic heart failure (right panel). 
High-resolution computed tomography scan of the chest 
reveals pulmonary edema (left panel).
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Conclusion
Evaluation of cardiac and pulmonary function and 
interactions between CHF and consequential chronic 
lung disease is complex and incompletely understood, 
often problematic and occasionally misleading. Both 
conditions are systemic disorders with overlapping 
pathophysiological processes, and they present diag-
nostic and therapeutic challenge. Pulmonary function 
is frequently abnormal, with a decrease in vital capac-
ity shown to precede clinical recognition of CHF. 
DLCO is often mildly reduced and does not normal-
ize following heart transplantation. Reduced lung 
compliance, increased dead space ventilation, and 
muscle weakness contribute to the preceding abnor-
malities in producing exercise limitation. Sleep apnea, 
particularly of the central variety, is associated with 
chronic CHF and confers worse prognosis. Various 
limitations of clinical evaluation may lead to diffi  cul-
ties in the diagnosis, and consequently in the treat-
ment of CHF, particularly when the presentation is 
atypical or when lung disease already exists. Th e result-
ing symptomatic and prognostic benefi ts outweigh 
those attainable by treating either condition alone. 
Additional studies providing new data on the patho-
genesis and management of patients with CHF are 
needed, with the purpose of trying to improve the 
quality of life, appropriate treatment, as well as sur-
vival of these patients. While many of these therapies 
will improve the care of patients with CHF, signifi cant 
reductions in the prevalence will require vigorous, 
multifaceted, preventive approaches. Only through 
high appreciation of the complex interactions between 
the heart and the lung, diagnostic and treatment-relat-
ed errors can be minimized. A high degree of coopera-
tion is ultimately required among cardiologists, pulm-
onologists and radiologists in order to better identify 
and manage these clinical entities. All clinicians at-
tending these patients should perform an integrated 
approach to objectively identify both diseases at an 
early stage, and to optimize control of respiratory and 
cardiovascular conditions.
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Sažetak
SRČANO-PLUĆNE INTERAKCIJE S POSLJEDIČNIM PLUĆNIM ABNORMALNOSTIMA 
U BOLESNIKA S KRONIČNIM SRČANIM ZATAJENJEM
I. Alerić, D. Katalinić i M. Krpan
Kronično srčano zatajenje značajno opterećuje bolesnika i njegovu obitelj kao i zdravstveni sustav u cjelini budući da je 
odgovorno za velik broj hospitalizacija. Unatoč golemim naporima u liječenju većine srčanih poremećaja iznimka ostaje kli-
nički sindrom kroničnog srčanog zatajenja učestalost kojega raste s neznatnim uspjehom produženja ukupnog preživljenja 
bolesnika. Kronično srčano zatajenje je povezano s visokom stopom pobola te nepovoljnom prognozom, čak lošijom uspore-
đujući sa stopom preživljenja za neke vrste zloćudnih tumora. Razlog porasta učestalosti kroničnog srčanog zatajenja u razvi-
jenim zemljama je produljenje ljudskog vijeka zahvaljujući mjerama suvremenog farmakološkog i intenzivnog liječenja, boljoj 
sekundarnoj profi laksi i starenju populacije. Kronična plućna bolest je česta pojava u bolesnika s kroničnim srčanim zataje-
njem. Oba stanja predstavljaju dijagnostički i terapijski izazov budući da dijele pojedine zajedničke čimbenike rizika i pato-
fi ziološke mehanizme nastanka. Cilj ovoga rada je ispitati različite mehanizme odgovorne za simptome kroničnog srčanog 
zatajenja s posljedičnim plućnim interakcijama i abnormalnostima plućne funkcije.
Ključne riječi: Srčano zatajivanje; Srčane bolesti; Plućne bolesti
